Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS COMPASS Pathways	$2.77 +4.1%	$4.05	$2.25 ▼ $8.54	$259.17M	2.25	1.18 million shs	3.36 million shs
CRVO CervoMed	$6.05 -14.9%	$8.18	$1.80 ▼ $20.63	$52.65M	-0.73	1.34 million shs	738,178 shs
DSGN Design Therapeutics	$3.57 -6.5%	$3.87	$2.60 ▼ $7.77	$202.67M	1.62	179,272 shs	169,350 shs
IMMP Prima BioMed	$1.64 +0.6%	$1.80	$1.32 ▼ $2.72	$239.50M	1.76	194,370 shs	56,504 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS COMPASS Pathways	0.00%	-40.17%	-33.09%	-5.78%	-52.32%
CRVO CervoMed	0.00%	-11.68%	-22.34%	-36.18%	-67.16%
DSGN Design Therapeutics	0.00%	-4.55%	-10.97%	-15.20%	+10.53%
IMMP Prima BioMed	0.00%	+2.50%	-16.75%	-11.83%	-40.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPS COMPASS Pathways	1.8996 of 5 stars	3.4	2.0	1.7	0.8	0.6
CRVO CervoMed	3.2086 of 5 stars	3.4	4.0	3.3	1.7	0.6
DSGN Design Therapeutics	1.3724 of 5 stars	2.0	1.0	3.3	2.5	0.6
IMMP Prima BioMed	1.4116 of 5 stars	3.5	1.0	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS COMPASS Pathways	2.86	Moderate Buy	$17.00	513.72% Upside
CRVO CervoMed	2.89	Moderate Buy	$27.63	356.61% Upside
DSGN Design Therapeutics	2.00	Hold	$4.00	12.04% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	326.83% Upside

Current Analyst Ratings Breakdown

Latest CRVO, IMMP, DSGN, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
6/11/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
5/12/2025	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
CRVO CervoMed	$9.74M	5.40	N/A	N/A	$4.50 per share	1.34
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.28 per share	N/A
IMMP Prima BioMed	$5.14M	46.60	N/A	N/A	$1.05 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
CRVO CervoMed	-$16.29M	-$2.18	N/A	N/A	N/A	-200.57%	-44.07%	-40.65%	8/8/2025 (Estimated)
DSGN Design Therapeutics	-$49.59M	-$0.99	N/A	N/A	N/A	N/A	-22.85%	-22.02%	8/4/2025 (Estimated)
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)

Latest CRVO, IMMP, DSGN, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/12/2025	Q1 2025	CRVO CervoMed	-$0.60	-$0.56	+$0.04	-$0.56	$1.70 million	$1.92 million
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS COMPASS Pathways	0.11	10.18	10.18
CRVO CervoMed	N/A	9.78	9.78
DSGN Design Therapeutics	N/A	28.37	28.37
IMMP Prima BioMed	N/A	18.86	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS COMPASS Pathways	46.19%
CRVO CervoMed	25.15%
DSGN Design Therapeutics	56.64%
IMMP Prima BioMed	2.32%

Insider Ownership

Company	Insider Ownership
CMPS COMPASS Pathways	3.93%
CRVO CervoMed	35.40%
DSGN Design Therapeutics	31.20%
IMMP Prima BioMed	3.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
CRVO CervoMed	4	8.70 million	5.62 million	Not Optionable
DSGN Design Therapeutics	40	56.77 million	39.06 million	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable

CRVO, IMMP, DSGN, and CMPS Headlines

Recent News About These Companies

Immutep (NASDAQ:IMMP) Cut to Sell at Wall Street Zen

June 14, 2025 | marketbeat.com

Immutep (NASDAQ:IMMP) Cut to "Sell" at Wall Street Zen

May 31, 2025 | marketbeat.com

Immutep’s Efti Combination Therapy Shows Promising Results in Soft Tissue Sarcoma Trial

May 28, 2025 | tipranks.com

Immutep Limited: Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025 | finanznachrichten.de

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025 | globenewswire.com

Immutep’s efti combination meets primary endpoint in Phase II soft tissue sarcoma trial

May 26, 2025 | sharecafe.com.auS

Immutep’s Efti Combination Therapy Achieves Success in Phase II Soft Tissue Sarcoma Trial

May 25, 2025 | tipranks.com

Immutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

May 16, 2025 | manilatimes.netM

Immutep reports promising lung cancer trial results

May 16, 2025 | investing.com

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

May 15, 2025 | finance.yahoo.com

Is Immutep Limited (IMMP) the Best Australian Stock to Buy According to Analysts?

May 15, 2025 | msn.com

Immutep’s Efti Combination Shows Promising Results in Lung Cancer Trial

May 14, 2025 | tipranks.com

Immutep Limited: Surging On Positive Head And Neck Data

May 8, 2025 | seekingalpha.com

Immutep's Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS

May 5, 2025 | manilatimes.netM

Immutep’s Efti Shows Promising Results in Head and Neck Cancer Trial

May 4, 2025 | tipranks.com

Immutep Quarterly Activities Report Q3 FY25

April 29, 2025 | finance.yahoo.com

Immutep Limited Reports First Patient Dosed in TACTI-004 Phase III Lung Cancer Trial and Updates on Clinical Progress

April 29, 2025 | quiverquant.comQ

Immutep Advances Cancer Trials with Promising Developments

April 28, 2025 | tipranks.com

Immutep to Participate in Upcoming Investor Conferences

April 2, 2025 | globenewswire.com

Immutep to Engage in Key Investor Conferences

April 1, 2025 | tipranks.com

Immutep: A Small Company With A Pipeline Resembling Big Pharma

March 31, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO, IMMP, DSGN, and CMPS Company Descriptions

COMPASS Pathways NASDAQ:CMPS

$2.77 +0.11 (+4.14%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.78 +0.00 (+0.18%)

As of 06/27/2025 07:57 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

CervoMed NASDAQ:CRVO

$6.05 -1.06 (-14.91%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.43 +0.38 (+6.28%)

As of 06/27/2025 06:27 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Design Therapeutics NASDAQ:DSGN

$3.57 -0.25 (-6.54%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.96 +0.39 (+10.78%)

As of 06/27/2025 07:04 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Prima BioMed NASDAQ:IMMP

$1.64 +0.01 (+0.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.63 -0.01 (-0.61%)

As of 06/27/2025 07:57 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time